Related Experiment Video
Updated: Sep 19, 2025
07:33
A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia
Published on: May 21, 2010
36.2K
Autosomal Recessive Cerebellar Ataxias: Translating Genes to Therapies
Brent L Fogel1, Thomas Klopstock2,3,4, David R Lynch5
1Departments of Neurology and Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.
Annals of Neurology
|June 4, 2025
Summary
Autosomal recessive cerebellar ataxias (ARCAs) are over 200 genetic disorders affecting balance and coordination. Genomic advances enable targeted treatments by understanding disease mechanisms for precision therapy development.
Area of Science:
- Neurogenetics
- Cerebellar Disorders
- Genomic Medicine
Background:
- Autosomal recessive cerebellar ataxias (ARCAs) encompass over 200 heterogeneous genetic conditions.
- These disorders lead to degeneration of the cerebellum and associated tracts, impairing balance and coordination.
- ARCAs represent a substantial global health burden.
Purpose of the Study:
- To highlight the impact of genomic testing on identifying ARCA subtypes.
- To emphasize the shift towards developing targeted mechanistic treatments for ARCAs.
- To underscore the importance of molecular classification for precision therapy development.
Main Methods:
- Review of advancements in genomic testing for ARCA diagnosis.
- Analysis of molecular classification strategies for identifying therapeutic targets.
- Discussion of pathways for novel therapeutic discovery and clinical trial development.
Main Results:
- Genomic testing has accelerated the identification of known ARCA genetic causes.
- Molecular classification reveals specific cellular, biochemical, and genetic targets.
- Precision therapies targeting underlying physiological pathways are becoming feasible.
Conclusions:
- Understanding ARCA pathogenesis is crucial for developing effective treatments.
- Targeted therapies offer promise for managing these complex neurological conditions.
- A structured approach is needed for translating research into clinical trials for ARCAs.
